Tag: FDA expanded indication

Home / FDA expanded indication

Categories

The FDA has broadened the indication for dostarlimab-gxly to include the treatment of endometrial cancer in combination with chemotherapy

August 2024: The Food and Drug Administration has granted approval for dostarlimab-gxly (Jemperli, GSK) in combination with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for t...
fda-expanded-indication

Scan the code